Apr 1, 2023
Shockwave Medical, Inc
SWAV
Statistics
$334.75 | Share Price |
$213.00 | Fair Value |
57.16% | Price vs Fair Value |
$12.7 B | Market Cap |
120.9% | 3yr Avg Revenue Growth |
Rising Revenues | |
Recurring Revenues | |
Regulatory Barriers Moat |
Stock Research and Updates
Research Article
Shockwave Is An Attractive Medical Device Firm
Updates
Updates: HRMY, MELI, SWAV
Feb 28, 2024
Quarterly Updates for TEAM, SWAV, GLBE
Aug 16, 2023
Updates on Celsius and Shockwave Medical
May 15, 2023
Fair Value Calculation Assumptions
Using a discounted free cash flow model with the following assumptions, the Fair Value estimate for Shockwave Medical, Inc (SWAV) is $213.00.
26.5% | Free Cash Flow Margin |
11.5% | Discount Rate / Required Rate of Return |
21.8% | Average Annual Revenue Growth (Years 1-5) |
2.6% | Average Annual Share Dilution (Years 1-5) |
14.0% | Average Annual Revenue Growth (Years 6-10) |
1.6% | Average Annual Share Dilution (Years 6-10) |
6.0% | Terminal Growth Rate |
$206.48 | Sum of Discounted Free Cash Flows |
$6.78 | Net "Excess" Cash/Debt Per Share |
$213.00 | Fair Value Estimate (rounded) |
Last updated Feb 28, 2024
Information contained on this website represents only the opinions of the author and should not be used as the sole basis for investing decisions. By using this site, you agree to all statements in the Site Policy.
Watch List
CRWD | 65.93% |
SEMR | -5.52% |
WDAY | 4.78% |
INTU | 23.36% |
SNOW | 19.74% |
SE | 53.03% |
PINS | 4.93% |
MA | 12.34% |
CMG | 83.45% |
GOOG | 36.20% |
TSM | -3.28% |
PSTG | 17.87% |
SMAR | 24.67% |
GTLB | 39.98% |
VEEV | 20.99% |
vs. Fair Value Estimates
Buy List
NYAX | -59.58% |
ASR | -33.12% |
HRMY | -48.34% |
YOU | -47.43% |
vs. Fair Value Estimates
Hold List
MSFT | -22.21% |
ODD | -22.00% |
FLYW | 20.21% |
CELH | -10.50% |
TOST | 48.67% |
CPNG | 5.74% |
HIMS | 10.18% |
PAYC | -19.86% |
MNDY | 30.81% |
GLBE | 11.38% |
ZS | 24.86% |
V | -12.29% |
ADSK | 11.10% |
NOW | 45.01% |
ABNB | -17.67% |
MELI | -20.86% |
FTNT | 2.49% |
TEAM | 18.70% |
ADBE | -13.10% |
vs. Fair Value Estimates